AL2846 capsules

DRUG3 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Neurofibromatosis and Malignant Peripheral Nerve Sheath TumorsPancreatic CancerThyroid Cancer

Phase 1

A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis

TerminatedNCT05011019

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors

Start: 2021-09-07End: 2024-02-02Updated: 2024-03-21

A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer

CompletedNCT06278493

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Pancreatic Cancer

Start: 2018-08-23End: 2023-05-01Updated: 2024-02-26

Phase 3

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

RecruitingNCT06860971

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Thyroid Cancer

Start: 2025-04-18End: 2028-01-31Target: 144Updated: 2025-12-31

Related Papers

Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer.

2025-01-06